AJR Am J Roentgenol
- DE OLIVEIRA CORREIA ET, Purysko AS, Paranhos BM, Shoag JE, et al
Reply to "Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on
Uncertain Evidence".
AJR Am J Roentgenol. 2024 Mar 20. doi: 10.2214/AJR.24.31168.
- TAKAHASHI T
Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on Uncertain
Evidence.
AJR Am J Roentgenol. 2024 Mar 20. doi: 10.2214/AJR.24.31070.
BJU Int
- PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
Reply to: Letter to the editor regarding the article 'Prostate cancer outcomes
following whole-gland and focal high-intensity focused ultrasound'.
BJU Int. 2024 Mar 22. doi: 10.1111/bju.16348.
- HAMDY FC, Albertsen PC, Donovan JL
Screening and active surveillance in prostate cancer: the dilemma continues.
BJU Int. 2024 Mar 21. doi: 10.1111/bju.16345.
- HUBER J, Karschuck P, Valdix J, Thomas C, et al
Online decision aid for patients with prostate cancer evaluated by 11 290
patients and 91 urologists in Germany.
BJU Int. 2024 Mar 20. doi: 10.1111/bju.16329.
- TAKAHASHI T
Active surveillance in all cases of screen-detected prostate cancer.
BJU Int. 2024 Mar 20. doi: 10.1111/bju.16344.
- VICKERS A
Magnetic resonance imaging-targeted prostate biopsy changed everything (so
everything has to change).
BJU Int. 2024;133:354-355.
- MCNICHOLAS DP, Parr NJ
Image intensifier-guided transperineal prostate biopsy for patients without a
rectum: novel technique.
BJU Int. 2024;133:487-490.
- JABBOUR T, Peltier A, Rocq L, Sirtaine N, et al
Magnetic resonance imaging targeted biopsy in biopsy-naive patients and the risk
of overtreatment in prostate cancer: a grading issue.
BJU Int. 2024;133:432-441.
BMC Cancer
- GUZMAN J, Weigelt K, Neumann A, Tripal P, et al
NanoLuc Binary Technology as a methodological approach: an important new tool for
studying the localization of androgen receptor and androgen receptor splice
variant V7 homo and heterodimers.
BMC Cancer. 2024;24:346.
Br J Cancer
- ZHANG Y, Stopsack KH, Wu K, Song M, et al
Multivitamin use after diagnosis and prostate cancer survival among men with
nonmetastatic prostate cancer.
Br J Cancer. 2024 Mar 15. doi: 10.1038/s41416-024-02651.
Cancer
- LIM FAT G, Alibhai S
Effect of hormonal therapies for prostate cancer on cognition: The ongoing search
for clarity.
Cancer. 2024 Mar 16. doi: 10.1002/cncr.35283.
Cancer Lett
- KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al
Chromatin activation with H3K36me2 and compartment shift in metastatic
castration-resistant prostate cancer.
Cancer Lett. 2024;588:216815.
Clin Cancer Res
- AGARWAL N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, et al
A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with
Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436.
Eur Radiol
- BOELLAARD TN, van Dijk-de Haan MC, Heijmink SWTPJ, Tillier CN, et al
Membranous urethral length measurement on preoperative MRI to predict
incontinence after radical prostatectomy: a literature review towards a proposal
for measurement standardization.
Eur Radiol. 2024;34:2621-2640.
Eur Urol
- VAUGIER L, Morvan C, Pasquier D, Buthaud X, et al
Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage
Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate
Cancer: OLIGOPELVIS (GETUG-P07).
Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024.
- NICKOLS NG, Tsai S, Kane N, Tran S, et al
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The
SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.
- MONTIRONI R, Cimadamore A, Giannarini G, Crestani A, et al
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish
Population.
Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024.
- O'CALLAGHAN M, Bulamu N, Gormly K, Jay A, et al
Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a
Prostate Health Check: A Prospective Cohort Study.
Eur Urol. 2024;85:395.
- WEBER M, Fendler WP, Ravi Kumar AS, Calais J, et al
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease
Extent and Overall Survival of Patients with High-risk Nonmetastatic
Castration-resistant Prostate Cancer: An International Multicenter Retrospective
Study.
Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.
- MOLLER F, Mansson M, Wallstrom J, Hellstrom M, et al
Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml:
Results from the Goteborg-2 Prostate Cancer Screening Trial.
Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024.
- GARCIA-RUIZ A, Macarro C, Zacchi F, Morales-Barrera R, et al
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in
Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical
Trial.
Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024.
- CUSSENOT O, Chambaz A, Hamdy FC
Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term
Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External
Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate
Cancer. Eur
Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024.
- BABOUDJIAN M, Diamand R, Uleri A, Beauval JB, et al
Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions
in Prostate Cancer Lead to Overtreatment?
Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.
- NIKITAS J, Rettig M, Shen J, Reiter R, et al
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer
(SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.
Int J Radiat Oncol Biol Phys
- LEE K, Lall R, Chopra S, Evans MJ, et al
SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for
Personalized Targeted Radionuclide Cancer Therapy.
Int J Radiat Oncol Biol Phys. 2024;118:1575-1584.
- MERCIER C, Billiet C, Ost P, Joye I, et al
Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic
Body Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2024;118:1490-1496.
- BAKER S, Lechner L, Liu M, Chang JS, et al
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer
Treated With SABR in the Phase 2 SABR-5 Trial.
Int J Radiat Oncol Biol Phys. 2024;118:1497-1506.
- YASAR B, Suh YE, Chapman E, Nicholls L, et al
Simultaneous focal boost with stereotactic radiotherapy for localised
intermediate to high-risk prostate cancer: Primary outcomes of the SPARC phase II
trial.
Int J Radiat Oncol Biol Phys. 2024 Mar 16:S0360-3016(24)00425.
J Clin Oncol
- YU JB, DeStephano DM, Jeffers B, Horowitz DP, et al
Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for
Prostate Cancer.
J Clin Oncol. 2024 Mar 20:JCO2301604. doi: 10.1200/JCO.23.01604.
J Urol
- HUSSAIN J, Sanchez-Salas R
Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain
Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
J Urol. 2024 May 19:101097JU0000000000003924. doi: 10.1097/JU.0000000000003924.
PLoS One
- SHAHROKHI NEJAD S, Golzari Z, Zangiabadian M, Salehi Amniyeh Khozani AA, et al
The association between zinc and prostate cancer development: A systematic review
and meta-analysis.
PLoS One. 2024;19:e0299398.
- PINKEOVA A, Tomikova A, Bertokova A, Fabinyova E, et al
Glycoprofiling of proteins as prostate cancer biomarkers: A multinational
population study.
PLoS One. 2024;19:e0300430.
Prostate
- HEERS H, Chwilka O, Huber J, Vogelmeier C, et al
VOC-based detection of prostate cancer using an electronic nose and ion mobility
spectrometry: A novel urine-based approach.
Prostate. 2024 Mar 18. doi: 10.1002/pros.24692.
- DI BELLO F, Baudo A, de Angelis M, Jannello LMI, et al
Other-cause mortality in incidental prostate cancer.
Prostate. 2024 Mar 20. doi: 10.1002/pros.24689.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016